Imbria Pharmaceuticals, Inc. is a biotechnology company developing therapies for cardiometabolic diseases, focusing on advancing their lead product candidate for non-obstructive hypertrophic cardiomyopathy.

Montara Therapeutics is a biotech company developing brain-selective therapies for central nervous system diseases using their BrainOnly™ platform.

Perfuze is a medical device company that develops catheters designed to improve stroke treatment by enhancing the trackability and delivery of aspiration catheters.

TRIMTECH Therapeutics is a biotech company developing targeted protein degradation therapeutics for neurodegenerative diseases using TRIMTAC degrader molecules.

AdvanCell is a clinical-stage radiopharmaceutical company developing innovative cancer therapies using targeted alpha-emitting radionuclides.

TRexBio is a biotechnology company developing novel therapies for inflammatory diseases using their Deep Biology platform to focus on immune homeostasis.

LoQus23 Therapeutics develops small molecule drugs to halt DNA instability and slow neurodegeneration in triplet repeat diseases like Huntington's disease.

SpectraWAVE, Inc. develops advanced medical imaging systems to improve coronary stenting procedures and enhance clinical decision-making in the treatment of coronary artery disease.

CSA Medical Inc. develops and commercializes the RejuvenAir System, a medical device designed to treat chronic bronchitis.

Harness Therapeutics is a biotech firm specializing in creating oligonucleotide-based drugs to treat neurodegenerative diseases by upregulating protein expression, with a current focus on advancing a treatment for Huntington's Disease towards clinical trials.

EyeBio is a clinical-stage ophthalmology biotechnology company focused on developing therapies for sight-threatening eye diseases and has expanded its Series A funding to $130 million.

Sitryx Therapeutics is a biopharmaceutical company that develops disease-modifying therapeutics for chronic autoimmune and inflammatory diseases by targeting and regulating cell metabolism.

Nimbus Therapeutics is a clinical-stage company that uses computational chemistry and structure-based drug design to develop novel therapies for immunology, cancer, and metabolic diseases.